ADMA Biologics reported third-quarter revenue of 141,102 and net income of 49,884, both in thousands, versus 134,224 and 36,428 in the prior-year quarter. Cash and cash equivalents were 124,555, also in thousands.
ADMA · Adma Biologics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $13.34
- Open
- $13.50
- Day range
- $13.10–13.59
- 52-week closing range
- $7.60–20.38
- Average volume, 30 days
- 3.7M
- Short interest
- 18.0M · 8.1% of shares · 7.1 days
- Short volume, last session
- 17%
- Last earnings
- Nov 4, 2026
- Latest filing
- 10-Q · Nov 4
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
ADMA Biologics reported 3Q 2026 total revenue of $141.1 million, up 5% year-over-year, and GAAP net income of $49.9 million, up 37%; it reiterated FY2026 revenue guidance of at least $530 million while increasing adjusted earnings expectations.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. ADMA reported Q2 2026 total revenue of $124.4 million with ASCENIV revenue up 24% year-over-year to $102.9 million, while BIVIGAM revenue declined 49% year-over-year to $19.4 million (though stabilizing sequentially). The company reiterated its full-year 2026 guidance, repurchased 7.1 million shares during the quarter, and continued to advance SG-001 toward a year-end pre-IND submission.
- + Gross margin expanded to 69% in Q2 2026 from 55% in the prior-year period, driven by ASCENIV mix and yield-enhanced manufacturing.
- + Adjusted EBITDA grew 22% year-over-year to $61.8 million and GAAP net income rose 11% to $37.8 million in Q2 2026.
- + Company repurchased 7.1 million shares in Q2 (13.8 million YTD, ~5.3% of shares outstanding) and remains on track to complete its $200 million-plus 2026 share repurchase target.
- − BIVIGAM revenue declined 49% year-over-year to $19.4 million in Q2 2026 amid continued competitive pricing and supply pressure in the U.S. standard immunoglobulin market.
- − Effective tax rate rose to 24.7% in Q2 2026 from 14.7% in the prior-year period, an increase of approximately 10 percentage points.
- − R&D expenses increased to $6.0 million in Q2 2026 from $1.0 million in the prior-year period, and are expected to step up again in Q4 for SG-001 conformance lot manufacturing.
- − SG&A expenses rose to $26.7 million in Q2 2026 from $22.2 million in the prior-year period, driven partly by higher professional and consulting fees associated with ongoing legal and related matters.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $121.5M | six months ended June 30, 2026 | — |
| Adjusted Net Income non-GAAP | $79.6M | six months ended June 30, 2026 | — |
| ASCENIV revenue growth | 26% | Six months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ADMA
this stock
Adma Biologics, Inc.
|
$2.96B | -26.9% | +43.9% | 17.3 | 8.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 4, 2026
- This year
- 17
ADMA Biologics reported third-quarter revenue of 141,102 and net income of 49,884, both in thousands, versus 134,224 and 36,428 in the prior-year quarter. Cash and cash equivalents were 124,555, also in thousands.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ADMA | +0.8% | +21.8% | +68.9% | +16.9% | -26.9% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +6.2% | +28.1% | +74.5% | +22.2% | -31.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.